TechForce Robotics, Inc., the acting subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), has completed the initial deployment of its LIM-E autonomous laboratory support robot at Oncotelic Therapeutics. This deployment fulfills Phase 1 objectives under a joint development agreement designed to evaluate robotics and AI-enhanced systems for future GMP-regulated pharmaceutical manufacturing and laboratory workflows. The move marks the company’s first operational entry into pharmaceutical and laboratory automation, extending its Robotics-as-a-Service (RaaS) platform from hospitality into the life sciences sector.
Laboratory and pharmaceutical operations increasingly face the same challenge that has accelerated automation across industries: how to improve efficiency while freeing highly trained personnel to focus on higher-value work. Researchers, technicians, and production staff often spend significant time on routine logistics tasks that, while necessary, do not directly advance scientific work or product development. As labor costs rise and productivity demands grow, pharmaceutical and biotechnology organizations are exploring automation solutions capable of supporting operational scalability without disrupting tightly regulated workflows.
TechForce Robotics is positioning itself to address that opportunity by extending its proven RaaS model from hospitality—where it has successfully deployed service robots—into the demanding environment of pharmaceutical labs. The LIM-E robot is designed to handle material transport, sample delivery, and other logistical tasks, allowing scientists to focus on research and development. The initial deployment at Oncotelic Therapeutics serves as a testbed for integrating robotics into GMP-regulated environments, with the potential to reduce operational costs and improve throughput.
A new strategic alliance with JJ Enterprise adds advanced manufacturing, machine vision, and precision engineering expertise that could support the expansion of high-precision AI-driven applications. This partnership is expected to enhance the capabilities of TechForce’s robotic platforms, enabling them to perform more complex tasks such as precise liquid handling, sorting, and inspection. The combination of robotics and AI could lead to higher accuracy and consistency in laboratory processes, which is critical for drug development and quality control.
The implications of this announcement are significant for the pharmaceutical industry. By adopting autonomous robots, companies can address labor shortages, reduce human error, and accelerate the pace of research. For TechForce Robotics, successful deployment in a GMP environment could open doors to larger contracts and partnerships with major pharmaceutical firms. The company’s move into lab automation also reflects a broader trend of cross-industry technology transfer, where solutions developed for one sector are adapted to solve problems in another.
For more information on TechForce Robotics and its parent company, visit the company’s newsroom at https://ibn.fm/NGTF. Updates on the joint development agreement and the LIM-E robot deployment can be found through TechMediaWire at https://www.TechMediaWire.com.
